Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice

Edit B. Olasz, Jooyoung Roh, Carole L. Yee, Ken Arita, Masashi Akiyama, Hiroshi Shimizu, Jonathan C. Vogel, Kim B. Yancey

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or major histocompatibility complex I (MHC I)-/- mice elicited IgG that bound human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt (detectable within 16±2 days), robust (titer ≥1,280), durable (present ≥380 days), and correlated with the involution and loss of Tg skin grafts. MHC II-/- mice grafted with Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4+ T cell interactions were crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP, has relevance to immune responses that may arise in patients with epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may block production of IgG against proteins in epidermal BM.

Original languageEnglish (US)
Pages (from-to)2807-2817
Number of pages11
JournalJournal of Investigative Dermatology
Volume127
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Bullous Pemphigoid
Grafts
Skin
Basement Membrane
Immunoglobulin G
Epidermolysis Bullosa
Transplants
Antigens
Keratin-14
T-cells
Genetic Databases
Autoantibodies
Blister
Major Histocompatibility Complex
Deposits
Cell Communication
Genes
Transgenic Mice
Edema
Neutrophils

ASJC Scopus subject areas

  • Dermatology

Cite this

Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. / Olasz, Edit B.; Roh, Jooyoung; Yee, Carole L.; Arita, Ken; Akiyama, Masashi; Shimizu, Hiroshi; Vogel, Jonathan C.; Yancey, Kim B.

In: Journal of Investigative Dermatology, Vol. 127, No. 12, 12.2007, p. 2807-2817.

Research output: Contribution to journalArticle

Olasz, Edit B. ; Roh, Jooyoung ; Yee, Carole L. ; Arita, Ken ; Akiyama, Masashi ; Shimizu, Hiroshi ; Vogel, Jonathan C. ; Yancey, Kim B. / Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. In: Journal of Investigative Dermatology. 2007 ; Vol. 127, No. 12. pp. 2807-2817.
@article{1fc397cd8d944561aad4a5cdba5f8380,
title = "Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice",
abstract = "Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or major histocompatibility complex I (MHC I)-/- mice elicited IgG that bound human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt (detectable within 16±2 days), robust (titer ≥1,280), durable (present ≥380 days), and correlated with the involution and loss of Tg skin grafts. MHC II-/- mice grafted with Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4+ T cell interactions were crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP, has relevance to immune responses that may arise in patients with epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may block production of IgG against proteins in epidermal BM.",
author = "Olasz, {Edit B.} and Jooyoung Roh and Yee, {Carole L.} and Ken Arita and Masashi Akiyama and Hiroshi Shimizu and Vogel, {Jonathan C.} and Yancey, {Kim B.}",
year = "2007",
month = "12",
doi = "10.1038/sj.jid.5700970",
language = "English (US)",
volume = "127",
pages = "2807--2817",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice

AU - Olasz, Edit B.

AU - Roh, Jooyoung

AU - Yee, Carole L.

AU - Arita, Ken

AU - Akiyama, Masashi

AU - Shimizu, Hiroshi

AU - Vogel, Jonathan C.

AU - Yancey, Kim B.

PY - 2007/12

Y1 - 2007/12

N2 - Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or major histocompatibility complex I (MHC I)-/- mice elicited IgG that bound human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt (detectable within 16±2 days), robust (titer ≥1,280), durable (present ≥380 days), and correlated with the involution and loss of Tg skin grafts. MHC II-/- mice grafted with Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4+ T cell interactions were crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP, has relevance to immune responses that may arise in patients with epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may block production of IgG against proteins in epidermal BM.

AB - Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or major histocompatibility complex I (MHC I)-/- mice elicited IgG that bound human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt (detectable within 16±2 days), robust (titer ≥1,280), durable (present ≥380 days), and correlated with the involution and loss of Tg skin grafts. MHC II-/- mice grafted with Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4+ T cell interactions were crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP, has relevance to immune responses that may arise in patients with epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may block production of IgG against proteins in epidermal BM.

UR - http://www.scopus.com/inward/record.url?scp=36248972519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248972519&partnerID=8YFLogxK

U2 - 10.1038/sj.jid.5700970

DO - 10.1038/sj.jid.5700970

M3 - Article

VL - 127

SP - 2807

EP - 2817

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 12

ER -